Related Experiment Videos
Control of chemotherapy-induced emesis
1Section of Hematology/Oncology, Vermont Cancer Center, University of Vermont, Burlington 05402.
The New England Journal of Medicine
|December 9, 1993
Summary
Advances in antiemetic drugs have significantly improved quality of life for chemotherapy patients. While significant progress has been made, challenges remain in understanding and treating anticipatory and delayed chemotherapy-induced vomiting.
Area of Science:
- Oncology
- Pharmacology
Background:
- Antiemetic drug development is crucial for improving cancer patient quality of life.
- Chemotherapy-induced nausea and vomiting (CINV) significantly impacts patient well-being.
Purpose of the Study:
- To review the progress and remaining challenges in antiemetic therapy for chemotherapy patients.
- To highlight the advancements in managing chemotherapy-induced emesis.
Main Methods:
- Review of historical and current data on antiemetic drug efficacy.
- Analysis of therapeutic outcomes in patients receiving chemotherapy.
Main Results:
- Dramatic reduction in vomiting episodes for patients receiving cisplatin, from a median of 12 to over 50% experiencing no vomiting within 24 hours.
- Significant improvements in managing acute chemotherapy-induced nausea and vomiting.
Conclusions:
- Antiemetic therapy has seen remarkable progress, substantially enhancing patient quality of life.
- Further research is needed to address the mechanisms and treatment of anticipatory and delayed chemotherapy-induced vomiting.